As explained by Peter Salgo, MD, and Yehuda Handelsman, MD, FACP, FACE, FNLA, the obesity guideline published in 2013 doesn’t offer pharmacotherapy treatment options. However, Dr Salgo cites efficacy data that support their use for weight loss.
Dr Salgo explores short- and long-term agents, many of which are now being used as combination therapy, and asks the panelists to discuss their approaches when treating patients with obesity.
Kari Uusinarkaus, MD, FAAFP, FNLA, explains that although pharmacotherapeutic agents are helpful adjuncts in the management of weight loss, not all patients respond to treatment. Dr Uusinarkaus adds that overcoming other treatment barriers still deserves attention.
Dr Handelsman and Jeffrey D. Dunn, PharmD, MBA, emphasize how cost and reimbursement issues with these agents will continue to challenge their overall success. Dr Dunn explains that because more treatment options are becoming available, a coordinated effort to provide coverage is necessary.
Dr Handelsman emphasizes that, although there are effective pharmacotherapeutic options, lifestyle modification remains important. Dr Handelsman explains that not all patients who are obese require medication. Patients with complications should consider pharmacotherapeutic agents in combination with lifestyle interventions. For this reason, physicians need to focus on each patient as an individual when making treatment decisions.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More